Incyte

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. 

CEO
William J. Meury
CEOWilliam J. Meury
Employees
2,844
Employees2,844
Headquarters
Wilmington, Delaware
HeadquartersWilmington, Delaware
Founded
1991
Founded1991
Employees
2,844
Employees2,844

INCY Key Statistics

Market cap
22.68B
Market cap22.68B
Price-Earnings ratio
13.84
Price-Earnings ratio13.84
Dividend yield
—
Dividend yield—
Average volume
1.90M
Average volume1.90M
High today
$112.06
High today$112.06
Low today
$108.00
Low today$108.00
Open price
$108.81
Open price$108.81
Volume
965.71K
Volume965.71K
52 Week high
$132.60
52 Week high$132.60
52 Week low
$83.46
52 Week low$83.46

Stock Snapshot

With a market cap of 22.68B, Incyte(INCY) trades at $111.92. The stock has a price-to-earnings ratio of 13.84.

During the trading session on 2026-10-14, Incyte(INCY) shares reached a daily high of $112.06 and a low of $108.00. At a current price of $111.92, the stock is +3.6% higher than the low and still -0.1% under the high.

Trading activity shows a volume of 965.71K, compared to an average daily volume of 1.9M.

The stock's 52-week range extends from a low of $83.46 to a high of $132.60.

The stock's 52-week range extends from a low of $83.46 to a high of $132.60.

INCY News

TipRanks 7h
Incyte price target raised to $115 from $105 at Truist

Truist analyst Srikripa Devarakonda raised the firm’s price target on Incyte (INCY) to $115 from $105 and keeps a Hold rating on the shares. The firm has update...

Barron's 19h
Incyte Corp. Advanced Charts | INCY - Barron's

...

Incyte Corp. Advanced Charts | INCY - Barron's
TipRanks 1d
Incyte Buy Rating Reiterated as KRAS G12D Asset Shows Differentiated Efficacy; $152 Price Target Maintained

Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Buy rating on Incyte, retaining the price target of $152.00. Mitchell Kapoor has given his Buy rating d...

Analyst ratings

52%

of 31 ratings
Buy
41.9%
Hold
51.6%
Sell
6.5%

More INCY News

Simply Wall St 2d
What Incyte Buyers Were Betting On

For Incyte shareholders, the return over the past year was 33.1%, including dividends. That outcome reads clean and simple. It did not feel that way on 9 Octobe...

What Incyte Buyers Were Betting On
TipRanks 5d
Incyte’s Latest Dermal PK Study: What Completed Early-Stage Data Mean for INCY Investors

Incyte (INCY) announced an update on their ongoing clinical study. Incyte (INCY) has completed a Phase 1 study titled “An Open-Label, Dermal Open-Flow Microper...

Simply Wall St 6d
Is Rare Disease Approval Altering The Investment Case For Incyte?

Incyte and Mirum Pharmaceuticals reported that the U.S. FDA previously approved Atebrioz (zilurgisertib), an oral ALK2 inhibitor for Fibrodysplasia Ossificans P...

Is Rare Disease Approval Altering The Investment Case For Incyte?
Simply Wall St 7d
Incyte Won New Approvals, Is The Pullback A Cheap Entry?

Incyte (INCY) moved back into focus for many investors after U.S. regulators cleared Atebrioz for fibrodysplasia ossificans progressiva, and partners reported e...

Incyte Won New Approvals, Is The Pullback A Cheap Entry?

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.